Kangfang Biotechnology (Cayman) Co., Ltd. (the "Company")'s unaudited condensed interim financial information for the six months ended June 30, 2024, shows that the Group's revenue was RMB 1,024.7 million, a decrease from RMB 3,676.9 million in the same period last year. Revenue mainly comes from product sales and license fee income, with product sales revenue of RMB 939.4 million and license fee income of RMB 85.3 million. The Group incurred a loss of RMB 249.3 million during the period, compared to a profit of RMB 2,489.5 million in the same period last year. The Group's main markets include Mainland China and the USA, and it has engaged in a series of transactions with non-controlling shareholders and their subsidiaries. The Group paid a total of RMB 35.1 million in compensation to management during the reporting period. The Company's shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited on April 24, 2020.

Kangfang Biotechnology (Cayman) Co., Ltd. (the "Company")'s unaudited condensed interim financial information for the six months ended June 30, 2024, shows that the Group's revenue was RMB 1,024.7 million, a decrease from RMB 3,676.9 million in the same period last year. Revenue mainly comes from product sales and license fee income, with product sales revenue of RMB 939.4 million and license fee income of RMB 85.3 million. The Group incurred a loss of RMB 249.3 million during the period, compared to a profit of RMB 2,489.5 million in the same period last year. The Group's main markets include Mainland China and the USA, and it has engaged in a series of transactions with non-controlling shareholders and their subsidiaries. The Group paid a total of RMB 35.1 million in compensation to management during the reporting period. The Company's shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited on April 24, 2020.